Semaglutide CAS:910463-68-2

Semaglutide is primarily used to improve glycemic control in adults with type 2 diabetes mellitus. It belongs to the class of GLP-1 receptor agonists, which work by mimicking the effects of the natural hormone GLP-1. GLP-1 is involved in glucose metabolism regulation by stimulating insulin secretion from pancreatic beta cells when blood sugar levels are high and inhibiting glucagon secretion from pancreatic alpha cells, which helps to lower blood sugar levels. Apart from its effects on glucose regulation, semaglutide also promotes weight loss by delaying gastric emptying and increasing satiety. This dual action makes it particularly beneficial for patients who struggle with both diabetes and overweight or obesity. Semaglutide is typically administered once weekly via subcutaneous injection. Clinical studies have shown that it can effectively reduce HbA1c levels (a marker of long-term blood sugar control) when used alone or in combination with other antidiabetic medications. It has also demonstrated cardiovascular benefits, reducing the risk of major adverse cardiovascular events in patients with established cardiovascular disease. In addition to its approved use in type 2 diabetes, semaglutide is being investigated for its potential in other metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and obesity. Ongoing research aims to explore its broader therapeutic applications and efficacy in diverse patient populations.